267 related articles for article (PubMed ID: 29514418)
1. Role of hepatitis B surface antigen in hepatitis B virus relapse after entecavir or tenofovir prophylaxis in patients undergoing cancer chemotherapy.
Kuo MT; Tseng PL; Chou YP; Chang KC; Tsai MC; Kuo YH; Hu TH; Hung CH; Wang JH; Lu SN; Chen CH
J Gastroenterol Hepatol; 2018 Oct; 33(10):1766-1772. PubMed ID: 29514418
[TBL] [Abstract][Full Text] [Related]
2. DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B.
Papatheodoridis GV; Rigopoulou EI; Papatheodoridi M; Zachou K; Xourafas V; Gatselis N; Hadziyannis E; Vlachogiannakos J; Manolakopoulos S; Dalekos GN
Antivir Ther; 2018; 23(8):677-685. PubMed ID: 30044765
[TBL] [Abstract][Full Text] [Related]
3. The incidence and predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients.
Chen CH; Hsu YC; Lu SN; Hung CH; Wang JH; Lee CM; Hu TH
J Viral Hepat; 2018 May; 25(5):590-597. PubMed ID: 29274189
[TBL] [Abstract][Full Text] [Related]
4. Predictors of Virological Suppression After Clinical Relapse in Patients Who Discontinued Entecavir or Tenofovir.
Fang HW; Yen YH; Hung CH; Wang JH; Hu TH; Lu SN; Chen CH
Dig Dis Sci; 2022 Jul; 67(7):3402-3411. PubMed ID: 34241753
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients.
Qiu YW; Huang LH; Yang WL; Wang Z; Zhang B; Li YG; Su TT; Zhou HY; Xu W; Wang XD; Dai YP; Gan JH
Int J Infect Dis; 2016 Feb; 43():43-48. PubMed ID: 26523639
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B relapse after entecavir or tenofovir alafenamide cessation under anti-viral prophylaxis for cancer chemotherapy.
Fang HW; Tseng PL; Hu TH; Wang JH; Hung CH; Lu SN; Chen CH
Virol J; 2024 Apr; 21(1):79. PubMed ID: 38570803
[TBL] [Abstract][Full Text] [Related]
7. Association Between Level of Hepatitis B Surface Antigen and Relapse After Entecavir Therapy for Chronic Hepatitis B Virus Infection.
Chen CH; Hung CH; Hu TH; Wang JH; Lu SN; Su PF; Lee CM
Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1984-92.e1. PubMed ID: 26073492
[TBL] [Abstract][Full Text] [Related]
8. Incidence and Factors Associated With HBV Relapse After Cessation of Entecavir or Tenofovir in Patients With HBsAg Below 100 IU/mL.
Tseng TN; Hu TH; Wang JH; Kuo YH; Hung CH; Lu SN; Jeng WJ; Chen CH
Clin Gastroenterol Hepatol; 2020 Nov; 18(12):2803-2812.e2. PubMed ID: 32360818
[TBL] [Abstract][Full Text] [Related]
9. Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg ≤ 200 IU/mL.
Yao CC; Hung CH; Hu TH; Lu SN; Wang JH; Lee CM; Chen CH
Sci Rep; 2017 May; 7(1):1839. PubMed ID: 28500322
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B.
Lee HA; Seo YS; Park SW; Park SJ; Kim TH; Suh SJ; Jung YK; Kim JH; An H; Yim HJ; Yeon JE; Byun KS; Um SH
Clin Mol Hepatol; 2016 Sep; 22(3):382-389. PubMed ID: 27729633
[TBL] [Abstract][Full Text] [Related]
11. Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation.
Kuo YH; Wang JH; Hung CH; Lu SN; Hu TH; Chen CH
Hepatol Int; 2021 Apr; 15(2):301-309. PubMed ID: 33665773
[TBL] [Abstract][Full Text] [Related]
12. Associations of HBV Genotype B vs C Infection With Relapse After Cessation of Entecavir or Tenofovir Therapy.
Chiu SM; Kuo YH; Wang JH; Hung CH; Hu TH; Lu SN; Chen CH
Clin Gastroenterol Hepatol; 2020 Dec; 18(13):2989-2997.e3. PubMed ID: 32353534
[TBL] [Abstract][Full Text] [Related]
13. Kinetics in HBsAg after Stopping Entecavir or Tenofovir in Patients with Virological Relapse but Not Clinical Relapse.
Tseng TN; Kuo YH; Hu TH; Hung CH; Wang JH; Lu SN; Chen CH
Viruses; 2022 May; 14(6):. PubMed ID: 35746660
[TBL] [Abstract][Full Text] [Related]
14. Preventing viral relapse with prophylactic tenofovir in hepatitis B carriers receiving chemotherapy: a phase IV randomized study in Taiwan.
Hsu CW; Chen SC; Wang PN; Wang HM; Chen YC; Yeh CT
Hepatol Int; 2024 Apr; 18(2):449-460. PubMed ID: 38376651
[TBL] [Abstract][Full Text] [Related]
15. Combined baseline HBcrAg and end-of-treatment HBsAg predict HBV relapse after entecavir or tenofovir cessation.
Tseng TN; Jeng WJ; Hu TH; Wang JH; Hung CH; Lu SN; Chen CH
J Antimicrob Chemother; 2023 Feb; 78(2):436-439. PubMed ID: 36478233
[TBL] [Abstract][Full Text] [Related]
16. The role of hepatitis B virus core-related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen-negative patients.
Huang PY; Wang JH; Hung CH; Lu SN; Hu TH; Chen CH
J Viral Hepat; 2021 Aug; 28(8):1141-1149. PubMed ID: 33932245
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B surface antigen loss and clinical outcomes between HBeAg-negative cirrhosis patients who discontinued or continued nucleoside analogue therapy.
Hung CH; Wang JH; Lu SN; Hu TH; Lee CM; Chen CH
J Viral Hepat; 2017 Jul; 24(7):599-607. PubMed ID: 28130815
[TBL] [Abstract][Full Text] [Related]
18. Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy.
Su TH; Yang HC; Tseng TC; Liou JM; Liu CH; Chen CL; Chen PJ; Chen DS; Liu CJ; Kao JH
J Infect Dis; 2018 Mar; 217(8):1193-1201. PubMed ID: 29300980
[TBL] [Abstract][Full Text] [Related]
19. Risk of renal events during tenofovir disoproxil fumarate and entecavir antiviral prophylaxis in HBsAg-positive cancer patients undergoing chemotherapy.
Lee IC; Chao Y; Li CP; Su CW; Lan KH; Lin HC; Hou MC; Huang YH
J Viral Hepat; 2018 Dec; 25(12):1599-1607. PubMed ID: 30125436
[TBL] [Abstract][Full Text] [Related]
20. Alternative Therapies for Chronic Hepatitis B Patients With Partial Virological Response to Standard Entecavir Monotherapy.
Chaung KT; O'Brien C; Ha NB; Nguyen NH; Trinh HN; Nguyen MH
J Clin Gastroenterol; 2016 Apr; 50(4):338-44. PubMed ID: 26646801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
